Publications by authors named "Giebel S"

Article Synopsis
  • Natural killer (NK) cells can detect and destroy malignant cells using specific receptors, and the study investigates how certain genetic variations in these receptors impact relapse and graft-versus-host disease (GVHD) after stem cell transplantation.
  • Researchers analyzed 1,638 genetic variations in 21 non-KIR NK cell receptor genes among 1,491 donors from multiple countries to assess their effects on relapse and GVHD, identifying eleven relevant polymorphisms.
  • Although some genetic variations showed potential links to NK cell activity in vitro, the overall findings did not demonstrate strong effects of these non-KIR NK cell receptors on HSCT outcomes, as associations were not confirmed in the replication cohort.
View Article and Find Full Text PDF

Despite new treatment strategies, graft-versus-host disease (GvHD) remains a formidable complication after allogeneic hematopoietic stem cell transplantation (HSCT). This study aimed to investigate the impact of polymorphisms and expression of MICA and NKG2D receptor on the development of GvHD in allogeneic HSCT recipients. Soluble MICA (sMICA) concentration was measured in serum collected 30 days after transplantation and the genetic variability of MICA and NKG2D genes was evaluated.

View Article and Find Full Text PDF

Leveraging every undergraduate application submitted by self-identified Hispanic applicants to the University of California system in the 2016 and 2017 application cycles, we show that a significant number of applicants claim Hispanic identity by virtue of European heritage. We subsequently demonstrate that Hispanic-identifying students of European descent are significantly more affluent and more likely to apply to selective University of California campuses than their non-European Hispanic peers. We comment on the practical implications of these disparities, as well as their relevance for studies of inequality in the social sciences and education.

View Article and Find Full Text PDF

The use of tyrosine kinase inhibitors (TKIs) during induction and consolidation, followed by allogeneic hematopoietic cell transplantation (allo-HCT), is a standard of care for patients with Philadelphia (Ph)-positive acute lymphoblastic leukemia (ALL). The goal of this study was to compare results of allo-HCT according to the type of TKI used pre-transplant, either imatinib, dasatinib or both. This was a retrospective, registry-based analysis including adult patients with Ph-positive ALL treated with allo-HCT between years 2010-2022.

View Article and Find Full Text PDF

Background: T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) molecule is a key regulator of the immune response by exerting an inhibitory effect on various types of immune cells. Understanding the role of TIM-3 in hematopoietic stem cell transplantation (HSCT) may improve transplant outcomes. Our study evaluated the potential association between TIM-3 polymorphisms, namely rs1036199 (A > C) or rs10515746 (C > A), changes which are located in exon 3 and the promoter region of the TIM-3 gene, and post-HSCT outcomes.

View Article and Find Full Text PDF

Choice of calcineurin inhibitor may impact the outcome of patients undergoing T-cell replete hematopoietic cell transplantation (HCT) with post-transplant cyclophosphamide (PT-Cy) and mycophenolate mofetil (MMF) for prophylaxis of graft-versus-host disease (GVHD). We retrospectively analyzed 2427 patients with acute myeloid leukemia (AML) in first remission transplanted from a haploidentical (n = 1844) or unrelated donor (UD, n = 583) using cyclosporine A (CSA, 63%) or tacrolimus (TAC, 37%) and PT-Cy/MMF. In univariate analysis, CSA and TAC groups did not differ in 2-year leukemia-free or overall survival, cumulative incidence (CI) of relapse or non-relapse mortality.

View Article and Find Full Text PDF

Allogeneic hematopoietic cell transplantation (allo-HSCT) stands as an effective treatment method for various hematologic malignancies. However, graft-versus-host disease (GvHD), an intricate immunological phenomenon where donor immune cells target recipient tissues, remains a significant challenge, particularly in mismatched unrelated donors (MMUD). Post-transplant cyclophosphamide (PTCy) has emerged as a promising immunosuppressive strategy, revolutionizing haploidentical transplantation and demonstrating promise in MMUD settings.

View Article and Find Full Text PDF

Non-cytotoxic innate lymphoid cells (ILCs) have been added to the list of immune cells that may contribute to the tumor microenvironment. Elevated levels of total ILCs and their subgroups have been reported in peripheral blood and tissue samples from patients with solid tumors, but their frequency in non-Hodgkin lymphomas, particularly diffuse large B-cell lymphoma (DLBCL), has not been clearly established. This study examined frequency and subset distribution in newly diagnosed DLBCL patients (nodal and extra-nodal) and compared it with blood specimens from healthy donors.

View Article and Find Full Text PDF

The aim of the present study was to determine the associations between the genetic variability and the expression and the risk of development of post-transplant complications after allogeneic hematopoietic stem cell transplantation (HSCT). HSCT recipients and their donors were genotyped for two polymorphisms (rs1065075, rs3828903). Moreover, the expression of a soluble form of MICB was determined in the recipients' serum samples after transplantation using the Luminex assay.

View Article and Find Full Text PDF

T-cell acute lymphoblastic leukemia (T-ALL) predominantly affects individuals in late childhood and young adulthood. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative modality particularly in the setting of poor risk genetics and/or persistent minimal residual disease. Limited studies have directly explored the impact of patient- and transplant-related factors on post-transplant outcomes in T-ALL.

View Article and Find Full Text PDF
Article Synopsis
  • A study compared the effectiveness of posttransplant cyclophosphamide (PTCy) versus conventional calcineurin inhibitor (CNI)-based regimens for preventing graft-versus-host disease (GVHD) in patients with Hodgkin lymphoma undergoing hematopoietic stem cell transplantation (HSCT) from HLA-matched donors.
  • Results showed that while PTCy was linked to slower recovery of blood cells, it significantly reduced the risk of chronic GVHD and improved long-term survival measures, including overall survival (OS) and progression-free survival (PFS).
  • Overall, PTCy exhibited better outcomes in reducing relapse rates and improving survival compared to CNI-based prophylaxis in this patient group, suggesting it may be a
View Article and Find Full Text PDF

Despite notable advancements in immunotherapy in the past decades, allogeneic hematopoietic stem cell transplantation (allo-HCT) remains a promising, potentially curative treatment modality. Only a limited number of studies have performed a direct comparison of two prevalent rabbit anti-thymocyte globulin (r-ATG) formulations-specifically, Thymoglobuline (ATG-T, formerly Genzyme) and Grafalon (ATG-G, formerly Fresenius). The primary objective of our retrospective analysis was to compare the outcomes of adult patients undergoing matched or mismatched unrelated donor (MUD/MMUD) allo-HCT, with a graft-versus-host disease (GvHD) prophylaxis based on either ATG-T or ATG-G.

View Article and Find Full Text PDF

Second allogeneic stem cell transplantation (alloSCT2) is among the most effective treatments for acute myeloid leukemia (AML) relapse after first alloSCT (alloSCT1). Long-term EBMT registry data were used to provide large scale, up-to-date outcome results and to identify factors for improved outcome. Among 1540 recipients of alloSCT2, increasing age, better disease control and performance status before alloSCT2, more use of alternative donors and higher conditioning intensity represented important trends over time.

View Article and Find Full Text PDF

Background: A genetic polymorphism, rs2204985, has been reported to be associated with the diversity of T-cell antigen receptor repertoire and TREC levels, reflecting the function of the thymus. As the thymus function can be assumed to be an important factor regulating the outcome of stem cell transplantation (SCT), it was of great interest that rs2204985 showed a genetic association to disease-free and overall survival in a German SCT donor cohort. Tools to predict the outcome of SCT more accurately would help in risk assessment and patient safety.

View Article and Find Full Text PDF

Purpose: Acute myeloid leukemia (AML) is a disease of older patients. Progress in allogeneic hematopoietic cell transplantation (allo-HCT) allowed the delivery of allo-HCT to older patients. We assessed changes over time in transplant characteristics and outcomes in patients with AML ages 65 years and above.

View Article and Find Full Text PDF

Clostridioides difficile infection (CDI) is the most common cause of infectious diarrhea after allogeneic hematopoietic cell transplantation (allo-HCT). The impact of CDI and its treatment on allo-HCT outcomes and graft-versus-host disease (GVHD), including gastrointestinal GVHD (GI-GVHD) is not well established. This multicenter study assessed real-life data on the first-line treatment of CDI and its impact on allo-HCT outcomes.

View Article and Find Full Text PDF
Article Synopsis
  • * Involving 2200 patients, the findings revealed that factors such as older donor age, use of female donors for male recipients, and the choice of peripheral blood donation were linked to poorer survival outcomes and increased risks of complications.
  • * The research suggests that prioritizing younger donors and male donors for male recipients can enhance transplant success, and utilizing bone marrow instead of peripheral blood may help reduce incidences of GVHD.
View Article and Find Full Text PDF

Objective: Hematopoietic stem cell transplantation (HSCT) is considered an integral part of therapy in many hematological and non-hematological malignancies. The procedure can be highly stressful for patients. The primary objective of this study was to compare stress assessments in HSCT patients, depending on their stress coping style (CS) and type of treatment (autologous vs.

View Article and Find Full Text PDF

Experts from the European Leukemia Net (ELN) working group for adult acute lymphoblastic leukemia have identified an unmet need for guidance regarding management of adult acute lymphoblastic leukemia (ALL) from diagnosis to aftercare. The group has previously summarized their recommendations regarding diagnostic approaches, prognostic factors, and assessment of ALL. The current recommendation summarizes clinical management.

View Article and Find Full Text PDF

Working groups of the European LeukemiaNet have published several important consensus guidelines. Acute lymphoblastic leukemia (ALL) has many different clinical and biological subgroups and the knowledge on disease biology and therapeutic options is increasing exponentially. The European Working Group for Adult ALL has therefore summarized the current state of the art and provided comprehensive consensus recommendations for diagnostic approaches, biologic and clinical characterization, prognostic factors, and risk stratification as well as definitions of endpoints and outcomes.

View Article and Find Full Text PDF

Secondary acute lymphoblastic leukemia (s-ALL) comprises up to 10% of ALL patients. However, data regarding s-ALL outcomes is limited. To answer what is the role of allogeneic hematopoietic cell transplantation (HCT) in s-ALL, a matched-pair analysis in a 1:2 ratio was conducted to compare outcomes between s-ALL and de novo ALL (dn-ALL) patients reported between 2000-2021 to the European Society for Blood and Marrow Transplantation registry.

View Article and Find Full Text PDF
Article Synopsis
  • - Graft-versus-host disease (GVHD) significantly impacts patient health post-allogeneic hematopoietic stem-cell transplantation, prompting new drug approvals and clinical practice changes in its management over the last three years.
  • - The European Society for Blood and Marrow Transplantation (EBMT) convened a panel of 23 experts to update clinical recommendations using the GRADE process and PICO questions to ensure standardized treatment approaches.
  • - Key updates include making ruxolitinib the standard care for steroid-refractory GVHD, using rabbit anti-T-cell globulin or post-transplantation cyclophosphamide for GVHD prevention, and adding belumosudil for treating steroid-refractory chronic GVHD.
View Article and Find Full Text PDF
Article Synopsis
  • Post-transplantation cyclophosphamide (PTCy) is being studied for its effectiveness in preventing graft-versus-host disease (GVHD) in patients with Hodgkin lymphoma (HL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  • The study compared the outcomes of HSCT between patients using HLA-matched donors (sibling and unrelated) and haploidentical donors, analyzing data from 2010 to 2020.
  • Results indicated that HLA-matched donor HSCT had better outcomes, including higher platelet engraftment and lower rates of acute GVHD and nonrelapse mortality, leading to improved overall survival compared to haploidentical donor HSCT.
View Article and Find Full Text PDF